# US 9,040,103 B2 · Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,040,103 B2 - Document ID: US9040103B2 - Status: Granted - Kind: B2 - Application number: 13/581,015 - Filed: 2011-02-28 - Published: 2013-03-07 - Granted: 2015-05-26 - Earliest claimed: 2010-02-26 - Assignees: L'oreal; Institut Curie; Centre National De La Recherche Scientifique - Applicants: Laurent Marrot; Jérémie Soeur; Meng-Er Huang - Inventors: Laurent Marrot; Jérémie Soeur; Meng-Er Huang - Web page: https://patentgrep.com/patent/US9040103B2 ## CPC - A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender - A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates - A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras - A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention concerns various compositions comprising the essential oil of Origanum compactum or of Aniba rosaeodora or one of their constituents, preferably a major constituent, for use in the targeted treatment and prevention of keratoses in the transformation phase and of carcinomas originating from these keratoses, and more particularly of keratoses induced by solar radiation on the skin of a subject. More particularly, the present invention concerns compositions based on the essential oil of oregano or of rosewood, or on linalool, thymol or carvacrol. ## Claims ### Claim 1 A method for the targeted treatment of keratoses in the transformation phase, of pre-cancerous or cancerous keratinocytes or of carcinoma originating from the transformation of keratoses, in human beings, comprising applying a composition comprising an essential oil extracted from plants of the genus Origanum or Aniba, or comprising at least one of the constituents of the essential oils of Origanum compactum or of Aniba rosaeodora selected from thymol, carvacrol, and linalool. ### Claim 2 (depends on 1) The method according to claim 1, wherein said composition comprises the essential oil of Origanum compactum or of Aniba rosaeodora. ### Claim 3 (depends on 1) The method according to claim 1, wherein the cumulative proportions of linalool, thymol, and carvacrol in said composition are more than 15% by weight. ### Claim 4 (depends on 1) The method according to claim 1, wherein said composition comprises at least 15% by weight of the essential oil of Origanum compactum or of Aniba rosaeodora or of linalool, thymol, or carvacrol. ### Claim 5 (depends on 1) The method according to claim 1, wherein said composition comprises vegetable oils. ### Claim 6 (depends on 1) The method according to claim 1, wherein said composition is applied topically to the skin. ### Claim 7 (depends on 1) The method according to claim 1, wherein said keratoses are actinic keratoses. ### Claim 8 (depends on 1) The method according to claim 1, wherein said carcinoma is a spino-cellular carcinoma or a baso-cellular carcinoma. ### Claim 9 (depends on 1) The method according to claim 1, wherein said keratoses, cancerous keratinocytes, or carcinoma are characterized by cells carrying mutations in the p53 protein. ### Claim 10 (depends on 1) The method according to claim 1, wherein said composition is to be applied in association with another treatment against keratoses. ### Claim 11 (depends on 1) The method according to claim 1, wherein said composition is to be applied before, during, after, or alternating with another treatment against keratoses. ### Claim 12 (depends on 1) The method according to claim 1, wherein said targeted treatment is free of deleterious effects on normal keratinocytes. ### Claim 13 (depends on 1) The method according to claim 1, inducing a preferential cytotoxicity in hyperproliferative keratinocytes compared with non-hyperproliferative keratinocytes. ### Claim 14 (depends on 1) The method according to claim 1, wherein the essential oil or the constituent constitutes an active principle of the composition. ### Claim 15 (depends on 1) The method according to claim 1, wherein the cumulative proportions of linalool, thymol, and carvacrol in said composition are more than 20% by weight. ### Claim 16 (depends on 1) The method according to claim 1, wherein said composition comprises at least 20% by weight of the essential oil of Origanum compactum or of Aniba rosaeodora or of linalool, thymol, or carvacrol. ### Claim 17 (depends on 1) The method according to claim 1, wherein said composition is to be applied in association with a chemotherapy or a dynamic phototherapy (DPT). ### Claim 18 (depends on 1) The method according to claim 1, wherein said composition is to be applied before, during, after, or alternating with a treatment by chemotherapy or by dynamic phototherapy.